The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! The stock decreased 3.60% or $0.62 during the last trading session, hitting $16.61. About 1.87 million shares traded hands or 257.91% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 5.57% since March 1, 2016 and is downtrending. It has underperformed by 17.79% the S&P500.
The move comes after 5 months negative chart setup for the $653.56 million company. It was reported on Oct, 4 by Barchart.com. We have $15.28 PT which if reached, will make NASDAQ:HRTX worth $52.28 million less.
Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on November, 4. They expect $-1.11 earnings per share, down 76.19% or $0.48 from last year’s $-0.63 per share. After $-1.17 actual earnings per share reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.13% EPS growth.
Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage
Out of 6 analysts covering Heron Therapeutics (NASDAQ:HRTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Brean Capital maintained it with “Buy” rating and $45 target price in Monday, August 10 report. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Wednesday, September 23. The firm earned “Buy” rating on Wednesday, September 2 by Bank of America. The firm has “Buy” rating given on Monday, August 3 by Brean Capital. The firm has “Outperform” rating by Leerink Swann given on Wednesday, September 23. The firm earned “Buy” rating on Thursday, December 10 by Lake Street.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”
More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Nasdaq.com which released: “Oversold Conditions For Heron Therapeutics” on October 03, 2016, also Schaeffersresearch.com with their article: “Analyst Update: Heron Therapeutics Inc, Fred’s, Inc., and Cognizant Technology …” published on October 03, 2016, Fool.com published: “Here’s Why Heron Therapeutics, Inc. Stock Gained 25% Today” on September 23, 2015. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “Heron Therapeutics Has An Upcoming Approval” published on July 18, 2016 as well as Wsj.com‘s news article titled: “FDA Approves Heron Therapeutics Anti-nausea Drug Sustol” with publication date: August 10, 2016.
HRTX Company Profile
Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.